Bank of Montreal Can Has $40.44 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of Montreal Can grew its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 30.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,086,322 shares of the biotechnology company's stock after buying an additional 489,320 shares during the quarter. Bank of Montreal Can owned 0.90% of ADMA Biologics worth $40,443,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ADMA. D. E. Shaw & Co. Inc. raised its position in shares of ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock valued at $76,298,000 after buying an additional 1,442,799 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. First Turn Management LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter valued at approximately $13,293,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of ADMA Biologics during the 2nd quarter valued at approximately $6,468,000. Finally, Renaissance Technologies LLC grew its holdings in shares of ADMA Biologics by 28.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company's stock valued at $28,868,000 after purchasing an additional 575,100 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Down 7.9 %

ADMA traded down $1.72 during trading on Friday, reaching $20.11. 3,998,266 shares of the company's stock were exchanged, compared to its average volume of 3,622,832. The firm has a fifty day moving average price of $19.08 and a two-hundred day moving average price of $15.23. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64. The stock has a market capitalization of $4.75 billion, a PE ratio of 72.86 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same period in the prior year, the firm posted $0.01 EPS. As a group, equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 5.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.70% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ADMA. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. Finally, HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.